drugset / Trial / NCT03961867
Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
S-1 plus oxaliplatin has been proved better than S-1 alone for stage II or III gastric cancer. Docetaxel also showed excellent efficacy with S-1 in the postoperative setting for stage III gastric cancer. This trial is designed to investigate the efficacy and safety of S-1 plus docetaxel versus S-1 plus oxalipltin as adjuvant chemotherapy after D2 resection in stage II / III gastric cancer.
Timeline
- Start
- 2020-09-15
- Primary completion
- 2022-09
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 40 mg/m2 | — |
| Comparator | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Background | S-1 | Small molecule | 80 mg | Oral |
| Background | S-1 | Small molecule | 100 mg | Oral |
| Background | S-1 | Small molecule | 120 mg | Oral |